Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Briana M Choi"'
Autor:
Samantha J. Werts-Pelter, Briana M. Choi, Stephanie Mallahan, Nicole Person-Rennell, Alicia Allen
Publikováno v:
Women's Health Reports, Vol 5, Iss 1, Pp 161-169 (2024)
Introduction: Cigarette smoking is the most common cause of preventable cancers and other premature morbidity and mortality. Modifying hormonal patterns using hormonal contraceptives (HCs) may lead to improved smoking cessation outcomes in women, tho
Externí odkaz:
https://doaj.org/article/e6e0a8018e1741fbbb137430ae011f6c
Publikováno v:
Diseases, Vol 10, Iss 4, p 88 (2022)
Using real-world data, this retrospective cross-sectional study aimed to analyze the association between patient–physician communication and self-reported mental health from cancer patients using publicly available 2019 Medical Expenditure Panel Su
Externí odkaz:
https://doaj.org/article/f7b545ff23ee48ccb7db14c0652dec9c
Publikováno v:
Supportive Care in Cancer. 31
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f57db9baa56cf379449f3198a1fa691e
https://doi.org/10.1007/s00520-022-07479-4
https://doi.org/10.1007/s00520-022-07479-4
Autor:
Neda Alrawashdh, Jamie Vraney, Briana M Choi, Abdulaali R Almutairi, Ivo Abraham, Ali McBride
Publikováno v:
Future oncology (London, England). 18(19)
Chemotherapy is intended to kill fast-growing cancer cells but can also kill immune cells that are needed to prevent infections. When too many immune cells are killed by chemotherapy, patients with cancer may experience febrile neutropenia, a serious
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e49bbfbcd524632ebb919816963c1e0
https://pubmed.ncbi.nlm.nih.gov/35477322
https://pubmed.ncbi.nlm.nih.gov/35477322
Autor:
Jordyn Kreutzfeldt, Mavis Obeng-Kusi, Ricardo J. Estrada-Mendizabal, Briana M Choi, Ivo Abraham, Alejandro Recio-Boiles
Publikováno v:
Journal of Clinical Oncology. 41:667-667
667 Background: Due to the ever-changing front-line landscape therapeutic options for m-ccRCC, the second-line (2L) treatment decision remains challenging due to limited information comparing each of the options. We present a survival, efficacy, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2ec208093a0702aa46914bb0effe1a8
https://doi.org/10.1200/jco.2023.41.6_suppl.667
https://doi.org/10.1200/jco.2023.41.6_suppl.667
Autor:
Briana M. Choi, Rachel B. Abraham, Hala Halawah, Matthias Calamia, Mavis Obeng-Kusi, Neda Alrawashdh, Daniel Arku, Ivo Abraham
Publikováno v:
Journal of medical economics. 24(sup1)
To demonstrate how medical purchasing power parities (mPPP) may harmonize economic evaluations from different jurisdictions and enable comparisons across jurisdictions.We describe the use of mPPPs and illustrate this with an example of economic evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c67de252acced1358e39772488dba89
https://pubmed.ncbi.nlm.nih.gov/34866529
https://pubmed.ncbi.nlm.nih.gov/34866529
Publikováno v:
Journal of the American Pharmacists Association. 62:1623-1630.e2
There are limited data on the psychometric properties of instruments evaluating professional identity (PI) among student pharmacists.This study analyzed the psychometric properties of an instrument to assess student pharmacists' perception of their P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08dc1cae70c312f92f7d0e54c8443742
https://doi.org/10.1016/j.japh.2022.05.006
https://doi.org/10.1016/j.japh.2022.05.006
Autor:
Briana M Choi, Rachel B Abraham, Osama Aqel, Uche S Agu, Kristen C. Gregory, Mavis Obeng-Kusi, Matthias Calamia, Hala Halawah, Deniz Tugay, Ahmad Alamer, Ali McBride, Ivo Abraham
Publikováno v:
Journal of Clinical Oncology. 40:e20502-e20502
e20502 Background: Patients with stage 1B non-small cell lung cancer (NSCLC) who receive surgical resection are at continued risk of disease recurrence and death after the surgery. Osimertinib, a tyrosine kinase inhibitor indicated for epidermal grow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c7ab68a14725a5f9c585db7807d0589
https://doi.org/10.1200/jco.2022.40.16_suppl.e20502
https://doi.org/10.1200/jco.2022.40.16_suppl.e20502
Autor:
Briana M Choi, Osama Aqel, Rachel B Abraham, Mavis Obeng-Kusi, Matthias Calamia, Hala Halawah, Ahmad Alamer, Ali McBride, Ivo Abraham, Deniz Tugay
Publikováno v:
Journal of Clinical Oncology. 40:e20506-e20506
e20506 Background: Following surgical resection, patients with NSCLC require monitoring due to the risk of recurrence. Studies have demonstrated the clinical benefit of osimertinib, a tyrosine kinase inhibitor, as adjunctive therapy in surgically res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8f049aff5633fff0207f0627ca68f69
https://doi.org/10.1200/jco.2022.40.16_suppl.e20506
https://doi.org/10.1200/jco.2022.40.16_suppl.e20506
Autor:
Mavis Obeng-Kusi, Briana M Choi, Rachel B Abraham, Osama Aqel, Matthias Calamia, Hala Halawah, Deniz Tugay, Ahmad Alamer, Ali McBride, Ivo Abraham
Publikováno v:
Journal of Clinical Oncology. 40:e20505-e20505
e20505 Background: Patients with surgically resected EGFR+ NSCLC remain at risk of recurrence after surgery. Osimertinib, a tyrosine kinase inhibitor, had been assessed clinically as adjunctive therapy in surgically resected EGFR+ NSCLC including sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c2194c141949f51fefd3d8d4ff00481
https://doi.org/10.1200/jco.2022.40.16_suppl.e20505
https://doi.org/10.1200/jco.2022.40.16_suppl.e20505